Sionna Therapeutics Expands Cystic Fibrosis Pipeline with Multiple Clinical-Stage Compounds Through Collaboration with AbbVie
Wednesday, July 17, 2024
Sionna Therapeutics, a company in the clinical stage of life sciences dedicated to advancing treatments for cystic fibrosis (CF), has recently secured exclusive global rights to develop and commercialize multiple clinical-stage compounds through a licensing agreement with AbbVie. This agreement includes galicaftor (ABBV-2222), a CFTR corrector targeting transmembrane domain 1 (TMD1), navocaftor (ABBV-3067), a CFTR potentiator, and ABBV-2851, a Phase 1 TMD1-directed corrector. Sionna will assume responsibility for development and intends to prioritize advancing one of these compounds alongside their own candidate, SION-109, as potential dual combination therapies with a first nucleotide binding domain (NBD1) stabilizer.
Mike Cloonan, President and CEO of Sionna, emphasized their strategy to enhance CF treatment by stabilizing the NBD1 of the CFTR protein. This approach aims to improve efficacy beyond current standards of care. Clinical studies conducted by AbbVie indicate that ABBV-2222 and ABBV-3067 are generally safe and well-tolerated, showing promising results in increasing lung function and reducing sweat chloride levels in CF patients.
Dr. Patrick Flume, clinical advisor to Sionna, highlighted the potential of these novel combinations to achieve superior efficacy compared to existing therapies, particularly for patients with the ΔF508 mutation, which severely impairs CFTR function. Sionna is also advancing its own NBD1 correctors, including SION-638, and plans to initiate Phase 1 studies for SION-451 and SION-719 in 2024, alongside their complementary modulators.
CF is caused by mutations in the CFTR gene, disrupting the production of normal mucus in vital organs. Sionna's innovative approach aims to address these mutations and potentially normalize CFTR function, offering new hope for CF patients worldwide.
Source: prnewswire.com
